-

Altasciences Expands Laboratory Capabilities in Columbia

LAVAL, Canada--(BUSINESS WIRE)--Altasciences’ laboratory facilities in Columbia, MO, are undergoing a significant expansion, with completion expected in 2023. The new 8,000-square-foot space will mirror Altasciences’ current bioanalytical laboratory in Laval, Québec, with state-of-the-art equipment and bioanalytical capabilities. This will supplement the service offering already available at Altasciences’ site in Seattle, WA, to support preclinical and clinical studies conducted in the U.S.

The laboratory’s strategic location, in close proximity to both preclinical and clinical facilities, reflects Altasciences’ focus on ensuring a seamless collaboration between teams, sites, and phases of development.

We are very excited about the laboratory expansion at our Columbia site. With this additional full-service, state-of-the-art bioanalytical and flow cytometry laboratory, we look forward to continuing to provide our usual high-quality, timely analyses of study samples for our clients,” said Lynne Le Sauteur, Vice President, Laboratory Sciences, at Altasciences.

Conveniently located in the Midwest, the Columbia site is near the fast-growing university town that is easily accessible from across the country. The bioanalytical laboratory will contain 48 workbenches in an open space, with services that include mass spectrometry and ligand binding assays, flow cytometry, biomarkers, as well as cell culture.

At Altasciences, we continue to increase capacity in support of our strategic growth plan, and look forward to the completion of this new laboratory to supplement our existing North American service offering,” stated Andy Brown, Columbia Site Director, at Altasciences.

About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.

Contacts

Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com

Altasciences

Details
Headquarters: Laval, Canada
CEO: Chris Perkin
Employees: 2,000+
Organization: PRI

Release Versions

Contacts

Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com

Social Media Profiles
More News From Altasciences

Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough

LAVAL, Québec--(BUSINESS WIRE)--Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025. The POC demonstrated the extension of AI-driven efficiencies from clinical reporting into nonclinical workflows, marking a significant step forward in...

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™

LAVAL, Québec--(BUSINESS WIRE)--Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Thera...

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

LAVAL, Québec & RADNOR, Pa.--(BUSINESS WIRE)--Altasciences, a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals...
Back to Newsroom